Superworth

Entrada Therapeutics PE ratio TRDA

Share price divided by earnings per share over the last twelve months, since 2024.

Today, Oct 23, 2026
n/m
losses over the last year
Last meaningful
10.3×
Jun 2025
Peer median
11.3×

Entrada Therapeutics has no meaningful PE ratio today: it lost $3.96 a share over the last twelve months, and a PE needs earnings.

It was last meaningful in Jun 2025, at 10.3×.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
202510.3×4.1×11.5×
202410.9×5.0×27.3×

Against its peers

Companies in Drug Manufacturers - General nearest Entrada Therapeutics' size, closest first, today.

CompanyPE ratio
TRDAEntrada Therapeuticsn/m
NATRNatures Sunshine Products12.0×
LFVNLifevantage14.7×
SPROSpero Therapeutics10.1×
ARVNArvinas45.6×
PBYIPuma Biotechnology21.2×
IRWDIronwood Pharmaceuticals4.5×
ZVRAZevra Therapeutics10.5×
CRMDCorMedix3.7×
ATNMActinium Pharmaceuticals4.2×
COLLCollegium Pharmaceutical18.5×
Peer median11.3×

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Entrada Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.